ANIP - ANI Pharmaceuticals SVP & CFO Sold $510K In Company Stock | Benzinga
Stephen P Carey, SVP & CFO at ANI Pharmaceuticals (NASDAQ:ANIP), executed a substantial insider sell on March 11, according to an SEC filing.
What Happened: Carey's recent Form 4 filing with the U.S. Securities and Exchange Commission on Monday unveiled the sale of 7,787 shares of ANI Pharmaceuticals. The total transaction value is $510,437.
In the Tuesday's morning session, ANI Pharmaceuticals's shares are currently trading at $66.13, experiencing a down of 0.0%.
Discovering ANI Pharmaceuticals: A Closer Look
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
ANI Pharmaceuticals's Financial Performance
Revenue Growth: ANI Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 39.71%. This indicates a substantial increase in the company's top-line earnings. In comparison ...